Acorda Therapeutics Strengthens Patent Portfolio on the Neuregulins.HAWTHORNE, N.Y. -- Acorda Therapeutics announced today that it has been awarded a new patent on its neuregulins products. This patent covers compositions of matter for the NRG NRG Energy NRG NRG Energy, Inc. NRG Natural Resources Group NRG New Radiancy Group NRG Network Referral Group NRG Network Resource Grapher NRG Numerics Rapporteur Group NRG Neuroprosthetics Research Group NRG notional requirements generator 2 family of growth factors as well as methods of production for NRG2. The addition of this patent broadens Acorda's existing neuregulin portfolio. NRG2 has potential applications in multiple sclerosis, spinal cord injury Spinal Cord Injury Definition Spinal cord injury is damage to the spinal cord that causes loss of sensation and motor control. Description Approximately 10,000 new spinal cord injuries (SCIs) occur each year in the United States. , Parkinson's disease Parkinson's disease or Parkinsonism, degenerative brain disorder first described by the English surgeon James Parkinson in 1817. When there is no known cause, the disease usually appears after age 40 and is referred to as Parkinson's disease. and chronic heart failure. The Company plans to continue to file patents in support of the neuregulins program. About Neuregulins The neuregulins are a class of naturally-occurring protein growth factors, which have multiple effects on the nervous system and potential therapeutic applications in central nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency and cardiac indications. Growth factors are proteins that bind to receptors on the cell surface, with the primary result of activating cellular survival, proliferation and/or differentiation. Many growth factors are quite versatile, stimulating cellular division in numerous different cell types; while others are specific to a particular cell-type. About Acorda Therapeutics Acorda Therapeutics, a privately-held biotechnology company, is developing therapies for spinal cord injury (SCI (Scalable Coherent Interface) An IEEE standard for a high-speed bus that uses wire or fiber-optic cable. It can transfer data up to 1GBytes/sec. (hardware) SCI - 1. Scalable Coherent Interface. 2. UART. ), multiple sclerosis (MS) and related nervous system disorders. The Company's marketed products include ZANAFLEX(R)CAPSULES (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity spasticity /spas·tic·i·ty/ (spas-tis´i-te) the state of being spastic; see spastic (2). spas·tic·i·ty n. 1. A spastic state or condition. 2. Spastic paralysis. . For full prescribing information, please go to www.zanaflexcapsules.com. Acorda's lead clinical-stage product is Fampridine-SR, which is being developed for both MS and SCI. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion